377Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive bio-
marker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006;5:2613–23.
Lukes L, Crawford N, Walker R, Hunter KW. The origins of breast cancer prognostic gene expres-
sion profi les. Cancer Res. 2009;69:310–8.
Luster M, Weber T, Verburg FA. Differentiated thyroid cancer-personalized therapies to prevent
overtreatment. Nat Rev Endocrinol. 2014;10:563–74.
Mackensen A, Meidenbauer N, Vogl S, et al. Phase I study of adoptive T-cell therapy using antigen-
specifi c CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol.
2006;24:5060–9.
Magnani L, Stoeck A, Zhang X, et al. Genome-wide reprogramming of the chromatin landscape
underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A.
2013;110:E1490–9.
Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-
cancer cells. NEJM. 2008;359:366–77.
Manjili MH. The inherent premise of immunotherapy for cancer dormancy. Cancer Res.
2014;74:6745–9.
Manuyakorn A, Paulus R, Farrell J, et al. Cellular histone modifi cation patterns predict prognosis
and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J
Clin Oncol. 2010;28:1358–65.
Maris JM, Hii G, Gelfand CA, et al. Region-specifi c detection of neuroblastoma loss of heterozy-
gosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Res.
2005;15:1168–76.
Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC:
prognostic importance in glioblastoma multiforme. J Neurooncol. 2007;82:133–9.
McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting Notch, a key pathway for ovarian cancer
stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012;109:
E2939–48.
Merlo A, Turrini R, Dolcetti R, et al. Adoptive cell therapy against EBV-related malignancies: a
survey of clinical results. Expert Opin Biol Ther. 2008;8:1265–94.
Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-
EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.
Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI bio-
marker for early stratifi cation of clinical brain tumor response. Proc Natl Acad Sci U S A.
2005;102:5524–9.
Myers CL, Dunham MJ, Kung SY, Troyanskaya OG. Accurate detection of aneuploidies in array
CGH and gene expression microarray data. Bioinformatics. 2004;20:3533–43.
Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 2007;450:1235–9.
Noguchi M, Kakuma T, Uemura H, et al. A randomized phase II trial of personalized peptide vac-
cine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with
castration resistant prostate cancer. Cancer Immunol Immunother. 2010;59:1001–9.
Norell H, Poschke I, Charo J, et al. Vaccination with a plasmid DNA encoding HER-2/neu together
with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clini-
cal trial. J Transl Med. 2010;8:53.
Nybakken GE, Bagg A. The genetic basis and expanding role of molecular analysis in the diagno-
sis, prognosis, and therapeutic design for myelodysplastic syndromes. J Mol Diagn. 2014;16:
145–58.
Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and
prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734–8.
Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors
occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Proc Natl Acad Sci U S A. 2012;109:E2127–33.
Ornish D, Magbanua M, Weidner G, et al. Changes in prostate gene expression in men undergoing
an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008;105:
8369–74.
References